Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Rises By 85.2%

Posted by Stanley Muller on Jun 4th, 2026

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS – Get Free Report) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 14,337 shares, an increase of 85.2% from the April 30th total of 7,742 shares. Based on an average trading volume of 20,059 shares, the short-interest ratio is presently 0.7 days. Currently, 0.0% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Read Our Latest Stock Analysis on Barinthus Biotherapeutics

Hedge Funds Weigh In On Barinthus Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rangeley Capital LLC lifted its stake in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Stock Up 6.2%

Shares of NASDAQ:BRNS opened at $0.70 on Thursday. The firm’s 50 day moving average price is $0.63 and its 200 day moving average price is $0.67. The stock has a market cap of $28.63 million, a price-to-earnings ratio of -0.54 and a beta of -0.40. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.14.

Barinthus Biotherapeutics Company Profile

(Get Free Report)

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.